Macular epiretinal brachytherapy in treated age-related macular degeneration (meritage): Month 24 safety and efficacy results

Robert Petrarca, Pravin U. Dugel, Michael Bennett, Adiel Barak, Dov Weinberger, Jeffrey Nau, Timothy L. Jackson*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


PURPOSE:: To evaluate the safety and efficacy of epimacular brachytherapy for the treatment of chronic, active neovascular age-related macular degeneration. METHODS:: A prospective, multicenter, interventional noncontrolled clinical trial recruited 53 participants with previously treated neovascular age-related macular degeneration. Participants underwent pars plana vitrectomy with a single 24 Gray dose of epimacular brachytherapy, delivered using an intraocular cannula containing a Strontium 90/Yttrium 90 source that was positioned over the active lesion. Participants were retreated with ranibizumab, administered monthly as needed, using predefined retreatment criteria. Coprimary outcomes at 24 months were the proportion of participants losing <15 Early Treatment of Diabetic Retinopathy Study letters and mean number of ranibizumab retreatments. RESULTS:: Over 24 months, 68.1% lost <15 letters with a mean of 8.7 ranibizumab retreatments. Mean change in visual acuity was -6.3 (standard deviation, 18.9) letters. There was one case of nonproliferative radiation retinopathy. CONCLUSION:: The apparent reduction in ranibizumab retreatment was less evident in Year 2 than Year 1, with the moderate reduction in visual acuity extending into the second year. Although radiation retinopathy occurred in one case, it was not vision threatening and safety remained acceptable.

Original languageEnglish
Pages (from-to)874-879
Number of pages6
Issue number5
StatePublished - May 2014
Externally publishedYes


  • Epimacular brachytherapy
  • Neovascular age-related macular degeneration
  • Radiation
  • Radiation retinopathy


Dive into the research topics of 'Macular epiretinal brachytherapy in treated age-related macular degeneration (meritage): Month 24 safety and efficacy results'. Together they form a unique fingerprint.

Cite this